Zosano Pharma Corp (NASDAQ: ZSAN) Announces Issuance of U.S. Patent for Acute Treatment of Migraine with M207

Zosano Pharma Corp (NASDAQ: ZSAN), a biopharmaceutical firm, announced that it had been granted the patent covering a method of M207 titled ‘Method of Rapidly Achieving Therapeutic Concentrations of Triptans for the Treatment of Migraines’ with the issuance of United States Patent No. 11,058,630. 

Steven Lo’s Statement

Steven Lo, President and CEO of Zosano, said that they continue to execute the pharmacokinetic study for submitting their NDA for M207 again. They are delighted to strengthen their patent portfolio for their innovative product candidate. Also, he adds that they believe M207, if authorized, may represent an impressive therapeutic choice for patients with debilitating migraines and is expected to discuss further with the FDA as they continue to seek approval. 

Moreover, the recently issued patent covers procedures for releasing the active drug from Zosano’s microneedle system in about one minute and attaining potentially therapeutic levels as shortly as 30 minutes upon application. This current patent adds to Zosano’s M207 patent portfolio, which comprises two U.S patents with claims covering the configuration of matter and method used for M207 with expirations in 2037. 

About M207

M207 is the firm’s proprietary formulation of zolmitriptan utilizing its proprietary transdermal microneedle system to advance the acute treatment of migraine. Moreover, this system comprises drug coated titanium microneedles, and in M207. The needle is formulated to penetrate the stratum corneum, where the investigational drug dissolves and enters the blood. The firm announced statistically significant results in February 2017 from the ZOTRIP pivotal study. The minimum dose of 3.8 mg of M207 joined co-primary endpoints, attaining pain freedom and most difficult symptom freedom at 2 hours. 

Migraine is a highly dominant neurological disease influencing 12% of the United States population and 1 in 4 households. The person affected by migraine experiences disability, with 90% unable to function commonly. Migraine effects are totaled to lead to lost productivity costs like $36 billion annually in the U.S. 

Leave a Comment

Your email address will not be published.